Established in 1986, it is among the top 10 pharma companies in India by revenue. The drugmaker is a market leader in semi-synthetic penicillin, and is present in therapeutic areas including neurosciences and cardiovascular ailments. Around 70 percent of its turnover come from global markets. While analysts have preferred Aurobindo for its diversified portfolio and long product pipeline, they have also expressed concerns over the company's R&D quality and lack of significant launches in the US lately.